

# A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in *in vitro* fertilization

**Herman Tournaye<sup>1</sup>, Gennady T. Sukhikh<sup>2</sup>, Elke Kahler<sup>3,\*</sup>, and Georg Griesinger<sup>4</sup>**

<sup>1</sup>Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090 Brussels, Belgium <sup>2</sup>Research Centre for Obstetrics, Gynecology and Perinatology, Akademika Oparina Street, 4, 117497, Moscow, Russia <sup>3</sup>Clinical Development, Established Pharmaceuticals, Abbott Laboratories GmbH, Freundallee 9A, 30173 Hannover, Germany <sup>4</sup>Department of Gynecological Endocrinology and Reproductive Medicine, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

\*Correspondence address. E-mail: elke.kahler@abbott.com

*Hum Reprod* 2017;**32**:1019–1027

The authors would like to apologise for an error in the Materials and Methods section of this article. The suppliers of the placebo in Group 1 and Group 2 patient groups are incorrect. The placebo intravaginal capsules given to Group 1 patients are from Catalent (Germany). The oral placebo tablets given to Group 2 patients are from Abbott B.V. (The Netherlands). The authors would like to assure readers that this does not affect any content of the article.